EP1320621A4 - Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications - Google Patents
Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modificationsInfo
- Publication number
- EP1320621A4 EP1320621A4 EP01975214A EP01975214A EP1320621A4 EP 1320621 A4 EP1320621 A4 EP 1320621A4 EP 01975214 A EP01975214 A EP 01975214A EP 01975214 A EP01975214 A EP 01975214A EP 1320621 A4 EP1320621 A4 EP 1320621A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- hiv1
- nef
- pol
- gag
- enhanced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108020004705 Codon Proteins 0.000 title 1
- 229940021704 adenovirus vaccine Drugs 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
- 230000004048 modification Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- AIDS & HIV (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23318000P | 2000-09-15 | 2000-09-15 | |
| US233180P | 2000-09-15 | ||
| PCT/US2001/028861 WO2002022080A2 (en) | 2000-09-15 | 2001-09-14 | Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1320621A2 EP1320621A2 (en) | 2003-06-25 |
| EP1320621A4 true EP1320621A4 (en) | 2005-11-23 |
Family
ID=22876220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP01975214A Withdrawn EP1320621A4 (en) | 2000-09-15 | 2001-09-14 | Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1320621A4 (en) |
| JP (1) | JP2004508064A (en) |
| AU (2) | AU2001294562B2 (en) |
| CA (1) | CA2422882A1 (en) |
| WO (1) | WO2002022080A2 (en) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2393861A1 (en) * | 1999-12-17 | 2001-06-21 | Merck & Co., Inc. | Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef |
| AU2002337840B2 (en) | 2001-10-11 | 2007-08-09 | Msd Italia S.R.L. | Hepatitis C virus vaccine |
| AP2696A (en) | 2001-10-31 | 2013-07-17 | The South African Medical Res Council | HIV-1 subtype isolate regulatory/accessory genes, and modifications and derivatives thereof. |
| US20060165664A1 (en) * | 2002-03-13 | 2006-07-27 | Emini Emilio A | Method of inducing an enhanced immune response against hiv |
| AU2003226012B2 (en) | 2002-03-29 | 2007-05-24 | Merck Sharp & Dohme Corp. | Methods of virus production |
| EP1506287B1 (en) | 2002-05-14 | 2007-04-25 | Merck & Co., Inc. | Methods of adenovirus purification |
| CN1490056A (en) * | 2002-10-18 | 2004-04-21 | ��¡���ɵ°��̲��о����� | Immunization methods and compositions against HIV-1 |
| WO2004037294A2 (en) * | 2002-10-23 | 2004-05-06 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
| US20080153083A1 (en) | 2003-10-23 | 2008-06-26 | Crucell Holland B.V. | Settings for recombinant adenoviral-based vaccines |
| AU2003298361B2 (en) | 2002-12-17 | 2009-05-14 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
| EP1583833A1 (en) | 2003-01-03 | 2005-10-12 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Rhesus her2/neu, nucleotides encoding same, and uses thereof |
| EP1649020B1 (en) | 2003-07-21 | 2017-01-11 | MSD Italia S.r.l. | Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof |
| GB2406336A (en) * | 2003-09-24 | 2005-03-30 | Oxxon Pharmaccines Ltd | HIV Pharmaccines |
| US8188244B2 (en) | 2004-02-11 | 2012-05-29 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Carcinoembryonic antigen fusions and uses thereof |
| EP1780269B1 (en) | 2004-02-23 | 2009-07-08 | Crucell Holland B.V. | Virus purification methods |
| WO2005110492A2 (en) * | 2004-04-12 | 2005-11-24 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of using adenoviral vectors to induce an immune response |
| GB0417494D0 (en) | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
| EP1799836B1 (en) | 2004-10-13 | 2010-12-22 | Crucell Holland B.V. | Improved adenoviral vectors and uses thereof |
| EP1869171B2 (en) | 2005-04-11 | 2015-10-14 | Crucell Holland B.V. | Virus purification using ultrafiltration |
| EP1880012B1 (en) * | 2005-05-12 | 2015-07-08 | Glaxo Group Limited | Vaccine composition |
| AU2012201827B2 (en) * | 2005-05-12 | 2014-09-04 | Glaxo Group Limited | Vaccine composition |
| CN101365715B (en) | 2005-10-07 | 2013-03-27 | P·安杰莱蒂分子生物学研究所 | Matrix metalloproteinase 11 vaccine |
| EA021391B1 (en) * | 2007-03-02 | 2015-06-30 | Глаксосмитклайн Байолоджикалс С.А. | Method of raising an immune response, vaccine composition, use thereof and kit |
| US9717788B2 (en) | 2007-03-02 | 2017-08-01 | Glaxosmithkline Biologicals Sa | Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant |
| US8420104B2 (en) | 2007-08-03 | 2013-04-16 | Institut Pasteur | Lentiviral gene transfer vectors and their medicinal applications |
| EP2047861B1 (en) * | 2007-10-12 | 2019-07-31 | Institut Pasteur | Lentiviral gene transfer vectors suitable for iterative administration and their medicinal applications |
| EP2185195A2 (en) | 2007-08-16 | 2010-05-19 | Tripep Ab | Immunogen platform |
| LT2358757T (en) * | 2008-11-18 | 2018-11-26 | Beth Israel Deaconess Medical Center | Antiviral vaccines with improved cellular immunogenicity |
| SG194079A1 (en) | 2011-04-06 | 2013-11-29 | Biovaxim Ltd | Pharmaceutical compositions for preventing and/or treating an hiv disease in humans |
| JP5770952B2 (en) | 2012-03-12 | 2015-08-26 | クルセル ホランド ベー ヴェー | Batch of recombinant adenoviruses with modified ends |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| DK2920313T3 (en) | 2012-11-16 | 2019-09-02 | Beth Israel Deaconess Medical Ct Inc | RECOMBINANT ADENOVIRA AND ITS USE |
| ES2836432T3 (en) | 2015-03-18 | 2021-06-25 | Janssen Vaccines & Prevention Bv | Assays for Recombinant Expression Systems |
| EP3283634B1 (en) | 2015-04-14 | 2019-05-22 | Janssen Vaccines & Prevention B.V. | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
| CN109312362B (en) | 2016-06-20 | 2022-06-28 | 扬森疫苗与预防公司 | Efficient and balanced bidirectional promoter |
| MX2020004490A (en) | 2017-10-31 | 2020-08-13 | Janssen Vaccines & Prevention Bv | Adenovirus vectors and uses thereof. |
| MX2020004488A (en) | 2017-10-31 | 2020-08-13 | Janssen Vaccines & Prevention Bv | Adenovirus and uses thereof. |
| EP3703722B1 (en) | 2017-10-31 | 2024-06-12 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
| KR20200077559A (en) | 2017-10-31 | 2020-06-30 | 얀센 백신스 앤드 프리벤션 비.브이. | Adenovirus and uses thereof |
| EP3723771A4 (en) | 2017-12-11 | 2022-04-06 | Beth Israel Deaconess Medical Center, Inc. | RECOMBINANT ADENOVIRUS AND USES THEREOF |
| CN111057716B (en) * | 2019-07-27 | 2022-04-15 | 中国人民解放军军事科学院军事医学研究院 | Single plasmid vector system for packaging recombinant human adenovirus type 4 and application thereof |
| BR112022005268A2 (en) | 2019-10-03 | 2022-08-16 | Janssen Vaccines & Prevention Bv | ADENOVIRAL VECTORS AND USES THEREOF |
| CN112522276B (en) * | 2020-12-15 | 2022-07-15 | 武汉纽福斯生物科技有限公司 | EMC1 nucleotide sequence and application thereof |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996009399A2 (en) * | 1994-09-23 | 1996-03-28 | Somatix Therapy Corporation | Chimeric adenovirus for gene delivery |
| WO1996014061A1 (en) * | 1994-11-03 | 1996-05-17 | Cell Genesys, Inc. | Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods |
| WO1999002647A2 (en) * | 1997-07-10 | 1999-01-21 | Hepavec Ag Für Gentherapie | Cloning vectors for producing adenoviral minimal viruses |
| WO1999041397A1 (en) * | 1998-02-17 | 1999-08-19 | Oxford Biomedica (Uk) Limited | Anti-viral vectors |
| WO1999055132A2 (en) * | 1998-04-24 | 1999-11-04 | Introgene B.V. | Generation of packaging system for human recombinant adenoviral vectors |
| US6040174A (en) * | 1993-05-28 | 2000-03-21 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
| WO2000015819A1 (en) * | 1998-09-11 | 2000-03-23 | The Children's Medical Center Corporation | Packaging cell lines for hiv-derived retroviral vector particles |
| WO2000039302A2 (en) * | 1998-12-31 | 2000-07-06 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| WO2000055341A1 (en) * | 1999-03-17 | 2000-09-21 | Oxford Biomedica (Uk) Limited | Anti-viral vectors |
| WO2000075370A1 (en) * | 1999-06-03 | 2000-12-14 | Oxford Biomedica (Uk) Limited | In vivo selection method for determining inhibitory rna molecules |
| WO2001045748A1 (en) * | 1999-12-22 | 2001-06-28 | Merck & Co., Inc. | Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol |
| EP1156112A1 (en) * | 2000-05-18 | 2001-11-21 | Geneart GmbH | Synthetic gagpol genes and their uses |
| WO2002032943A2 (en) * | 2000-08-14 | 2002-04-25 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643579A (en) * | 1984-11-01 | 1997-07-01 | American Home Products Corporation | Oral vaccines |
| WO1996039178A1 (en) * | 1995-06-05 | 1996-12-12 | The Wistar Institute Of Anatomy And Biology | A replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
| US6019978A (en) * | 1995-06-05 | 2000-02-01 | The Wistar Institute Of Anatomy And Biology | Replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
-
2001
- 2001-09-14 AU AU2001294562A patent/AU2001294562B2/en not_active Ceased
- 2001-09-14 EP EP01975214A patent/EP1320621A4/en not_active Withdrawn
- 2001-09-14 WO PCT/US2001/028861 patent/WO2002022080A2/en active IP Right Grant
- 2001-09-14 AU AU9456201A patent/AU9456201A/en active Pending
- 2001-09-14 JP JP2002526335A patent/JP2004508064A/en not_active Withdrawn
- 2001-09-14 CA CA002422882A patent/CA2422882A1/en not_active Abandoned
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6040174A (en) * | 1993-05-28 | 2000-03-21 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
| WO1996009399A2 (en) * | 1994-09-23 | 1996-03-28 | Somatix Therapy Corporation | Chimeric adenovirus for gene delivery |
| WO1996014061A1 (en) * | 1994-11-03 | 1996-05-17 | Cell Genesys, Inc. | Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods |
| WO1999002647A2 (en) * | 1997-07-10 | 1999-01-21 | Hepavec Ag Für Gentherapie | Cloning vectors for producing adenoviral minimal viruses |
| WO1999041397A1 (en) * | 1998-02-17 | 1999-08-19 | Oxford Biomedica (Uk) Limited | Anti-viral vectors |
| WO1999055132A2 (en) * | 1998-04-24 | 1999-11-04 | Introgene B.V. | Generation of packaging system for human recombinant adenoviral vectors |
| WO2000015819A1 (en) * | 1998-09-11 | 2000-03-23 | The Children's Medical Center Corporation | Packaging cell lines for hiv-derived retroviral vector particles |
| WO2000039302A2 (en) * | 1998-12-31 | 2000-07-06 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| WO2000055341A1 (en) * | 1999-03-17 | 2000-09-21 | Oxford Biomedica (Uk) Limited | Anti-viral vectors |
| WO2000075370A1 (en) * | 1999-06-03 | 2000-12-14 | Oxford Biomedica (Uk) Limited | In vivo selection method for determining inhibitory rna molecules |
| WO2001045748A1 (en) * | 1999-12-22 | 2001-06-28 | Merck & Co., Inc. | Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol |
| EP1156112A1 (en) * | 2000-05-18 | 2001-11-21 | Geneart GmbH | Synthetic gagpol genes and their uses |
| WO2002032943A2 (en) * | 2000-08-14 | 2002-04-25 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization |
Non-Patent Citations (6)
| Title |
|---|
| ANDRE S ET AL: "INCREASED IMMUNE RESPONSE ELICITED BY DNA VACCINATION WITH A SYNTHETIC GP120 SEQUENCE WITH OPTIMIZED CODON USAGE", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 72, no. 2, February 1998 (1998-02-01), pages 1497 - 1503, XP002073767, ISSN: 0022-538X * |
| BRUCE ET AL: "Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus ENV antigen can induce both humoral and CTL immune responses in mice", JOURNAL OF GENERAL VIROLOGY, vol. 80, 1999, pages 2621 - 2628, XP002963542 * |
| HU Y-W ET AL: "ENZYME ACTIVITIES IN FOUR DIFFERENT FORMS OF HUMAN IMMUNODEFICIENCY VIRUS 1 POL GENE PRODUCTS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 88, no. 11, 1991, pages 4596 - 4600, XP002306309, ISSN: 0027-8424 * |
| JOSHI S ET AL: "Molecular biology of human immunodeficiency virus Type-1", TRANSFUSION SCIENCE, PERGAMON PRESS, OXFORD, GB, vol. 17, no. 3, September 1996 (1996-09-01), pages 351 - 378, XP004568809, ISSN: 0955-3886 * |
| KARACOSTAS VELISSARIOS ET AL: "Overexpression of the HIV-1 Gag-Pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles", VIROLOGY, vol. 193, no. 2, 1993, pages 661 - 671, XP002306310, ISSN: 0042-6822 * |
| MIYAKE KOICHI ET AL: "A new strategy for large scale preparation of high-titer HIV vectors using adenovirus-based expression vectors", BLOOD, vol. 96, 16 November 2000 (2000-11-16), pages 430A * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004508064A (en) | 2004-03-18 |
| EP1320621A2 (en) | 2003-06-25 |
| WO2002022080A8 (en) | 2003-01-16 |
| CA2422882A1 (en) | 2002-03-21 |
| WO2002022080A2 (en) | 2002-03-21 |
| WO2002022080A3 (en) | 2002-05-02 |
| AU2001294562B8 (en) | 2002-03-26 |
| WO2002022080A9 (en) | 2003-03-06 |
| AU9456201A (en) | 2002-03-26 |
| AU2001294562B2 (en) | 2007-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU9456201A (en) | Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications | |
| GB0023008D0 (en) | Improvements in vaccination | |
| MXPA02005950A (en) | Chair. | |
| MXPA02012652A (en) | Saliva testing and confirmation device. | |
| MXPA02009082A (en) | Polyglutamic acid-camptothecin conjugates and methods of preparation. | |
| ZA200104180B (en) | Portable oxygen concentrator. | |
| MX265024B (en) | Novel surfactants and formulations. | |
| GB0005268D0 (en) | Document creation and delivery | |
| MXPA03000753A (en) | Benzimidazole derivatives, preparation and therapeutic use thereof. | |
| AU5208401A (en) | 3-nitrogen-6,7-dioxygen steroids and uses related thereto | |
| AU4433702A (en) | Vaccines | |
| AU1463402A (en) | Cushioned, fiber-covered dental applicators | |
| HUP0202385A2 (en) | Feline calicivirus genes and vaccines, in particular recombined vaccines | |
| SI1043307T1 (en) | 3-amino-3-arylpropan-1-ol-derivates, their preparation and their use | |
| AU2868601A (en) | Biaryl compounds, their preparation and their use in therapy | |
| EP1345623A4 (en) | Immunogenic proteoliposomes, and uses thereof | |
| ZA99535B (en) | Oxygen generating device. | |
| EP1242441A4 (en) | Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef | |
| EP1242124A4 (en) | Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol | |
| MXPA01011720A (en) | Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods. | |
| SI1043306T1 (en) | 3-amino-3-arylpropan-1-ol-derivates, their preparation and use | |
| GB9922627D0 (en) | User interface generation | |
| MXPA01010701A (en) | Vaccine. | |
| IL152808A0 (en) | Vaccines, immunotherapeutics and methods for using the same | |
| TW447310U (en) | Twisting and drawing back type safe syringe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20030415 |
|
| AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: CASIMIRO, DANILO, R. Inventor name: TONER, TIMOTHY, J. Inventor name: SHIVER, JOHN, W. Inventor name: KASLOW, DAVID, C. Inventor name: CHEN, LING Inventor name: BETT, ANDREW, J. Inventor name: YOUIL, RIMA Inventor name: EMINI, EMILIO, A. |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20051007 |
|
| 17Q | First examination report despatched |
Effective date: 20061017 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20080805 |